| Field | Specification |
|---|---|
| Target | |
| Alternative names | Necrostatin 1S; Nec-1S; 7-Cl-O-Nec1 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C13H12ClN3O2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Necrostatin 2 racemate, also known as Necrostatin 1S, Nec-1S, or 7-Cl-O-Nec1, is a stable form of Necrostatin-1 and a potent, specific RIPK1 inhibitor that lacks the IDO-targeting effect[1]. It is supplied as a white to light yellow solid (C13H12ClN3O2, MW 277.71) at 99.57% purity.
Physical & Chemical Properties
| CAS Number | 852391-15-2 |
|---|---|
| Molecular Formula | C13H12ClN3O2 |
| Molecular Weight | 277.71 g/mol |
| Purity | 99.57% |
| Appearance | Solid |
| Color | White to light yellow |
| SMILES | ClC1=C2C(C(CC3C(N(C)C(N3)=O)=O)=CN2)=CC=C1 |
| Target | RIPK1 |
| Signaling Pathway | Apoptosis |
| Solubility | In Vitro: DMSO: ≥ 50 mg/mL (180.04 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 1 year; -20°C, 6 months. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 50 mg/mL (180.04 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 1 year) or -20°C (up to 6 months); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 3 mg/mL (10.80 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 3 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (30.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 3 mg/mL (10.80 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 3 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (30.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 3 mg/mL (10.80 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 3 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (30.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
RIPK1 autophosphorylation is potently inhibited by Necrostatin 2 racemate (Nec-1S) (1-100 μM; 1 h) in a dose-dependent manner[1].
In Vivo
A single i.v. dose of Necrostatin 2 racemate (Nec-1S) (6 mg/kg) guards against TNF-induced systemic inflammatory response syndrome (SIRS) and has no sensitization effect[1].
| Animal Model | Female C57BL/6J WT mice, SIRS model[1] |
|---|---|
| Dosage | 0.6 mg/kg or 6 mg/kg |
| Administration | Intravenous injection, once |
| Result | Showed protective effect at 6 mg/kg. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Dismantling the Necroptotic Engine: An Oral Theranostic Nanosponge for Ulcerative Colitis. Adv Mater 2026 Jan 16:e16297. PMID: 41546396
Bacterial ADP-heptose triggers stem cell regeneration in the intestinal epithelium following injury. Cell Stem Cell 2025 Aug 7;32(8):1235-1250.e6. PMID: 40651470
Kitasamycin overcomes ferroptosis and immunotherapy resistance by targeting the HUWE1-NCOA4-FTH1 axis. Autophagy 2026 Feb 15:1-19. PMID: 41612599
Linoleic acid accelerates osteoarthritis progression in male rats by targeting iron-sulfur clusters to drive ferroptosis in chondrocytes. Nat Commun 2026 Jul 8;17(1):8447. PMID: 42420321
Intrinsic temperature increase drives lipid metabolism towards ferroptosis evasion and chemotherapy resistance in pancreatic cancer. Nat Commun 2024 Oct 2;15(1):8540. PMID: 39358362
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome. Nat Commun 2021 Jun 30;12(1):4050. PMID: 34193871
SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors. Redox Biol 2024 Oct:76:103304. PMID: 39153252
Penfluridol Triggers GSDME-Mediated Immunogenic Pyroptosis to Potentiate Antitumor Immunotherapy. Adv Sci (Weinh) 2026 Jul 3:e76408. PMID: 42396980
Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's Disease. Adv Sci (Weinh) 2024 Aug;11(32):e2309021. PMID: 38923244
Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. Cell Rep Med 2026 Aug 18;7(8):102928. PMID: 42486098
